MedTech Innovator

The industry’s nonprofit global competition and accelerator for medical device, digital health, and diagnostic companies.

Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system.
### Table of Contents

<table>
<thead>
<tr>
<th>Sponsors</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>MedTech Innovator Showcase Schedule</td>
<td>5</td>
</tr>
<tr>
<td>2Morrow</td>
<td>7</td>
</tr>
<tr>
<td>Abreos Biosciences</td>
<td>8</td>
</tr>
<tr>
<td>Access Vascular</td>
<td>9</td>
</tr>
<tr>
<td>Advanced Prenatal Therapeutics</td>
<td>10</td>
</tr>
<tr>
<td>Alleviant Medical</td>
<td>11</td>
</tr>
<tr>
<td>Allotrope Medical</td>
<td>12</td>
</tr>
<tr>
<td>Aqueduct Critical Care</td>
<td>13</td>
</tr>
<tr>
<td>Arterys</td>
<td>14</td>
</tr>
<tr>
<td>Avenda Health</td>
<td>15</td>
</tr>
<tr>
<td>Centerline Biomedical</td>
<td>16</td>
</tr>
<tr>
<td>Day Zero Diagnostics</td>
<td>17</td>
</tr>
<tr>
<td>EBS Technologies</td>
<td>18</td>
</tr>
<tr>
<td>Encellin</td>
<td>19</td>
</tr>
<tr>
<td>Evoke Medical</td>
<td>20</td>
</tr>
<tr>
<td>Eximis Surgical</td>
<td>21</td>
</tr>
<tr>
<td>ExplORer Surgical</td>
<td>22</td>
</tr>
<tr>
<td>Genetesis</td>
<td>23</td>
</tr>
<tr>
<td>Genomic Expression</td>
<td>24</td>
</tr>
<tr>
<td>GreenLight Medical</td>
<td>25</td>
</tr>
<tr>
<td>Harbor MedTech</td>
<td>26</td>
</tr>
<tr>
<td>HemaFlo Therapeutics</td>
<td>27</td>
</tr>
<tr>
<td>Innoblative Designs</td>
<td>28</td>
</tr>
<tr>
<td>Landsdowne Laboratories</td>
<td>29</td>
</tr>
<tr>
<td>M&amp;S Biotics</td>
<td>30</td>
</tr>
<tr>
<td>MetaOptima</td>
<td>31</td>
</tr>
<tr>
<td>mOm Incubators</td>
<td>32</td>
</tr>
<tr>
<td>Myonic</td>
<td>33</td>
</tr>
<tr>
<td>MYOVUE</td>
<td>34</td>
</tr>
<tr>
<td>Nanowear</td>
<td>35</td>
</tr>
<tr>
<td>Nexeon MedSystems</td>
<td>36</td>
</tr>
<tr>
<td>NovaGray</td>
<td>37</td>
</tr>
<tr>
<td>OncoTab, Inc.</td>
<td>38</td>
</tr>
<tr>
<td>Osso VR</td>
<td>39</td>
</tr>
<tr>
<td>Otricath</td>
<td>40</td>
</tr>
<tr>
<td>palmm</td>
<td>41</td>
</tr>
<tr>
<td>Patientory</td>
<td>42</td>
</tr>
<tr>
<td>PeriCor</td>
<td>43</td>
</tr>
<tr>
<td>PharmaJet</td>
<td>44</td>
</tr>
<tr>
<td>Pneumonics, Inc</td>
<td>45</td>
</tr>
<tr>
<td>Promaxo</td>
<td>46</td>
</tr>
<tr>
<td>Redox</td>
<td>47</td>
</tr>
<tr>
<td>Revolutionary Medical Devices</td>
<td>48</td>
</tr>
<tr>
<td>RxAssurance</td>
<td>49</td>
</tr>
<tr>
<td>Selio Medical</td>
<td>50</td>
</tr>
<tr>
<td>Trayt Health</td>
<td>51</td>
</tr>
<tr>
<td>VADovations</td>
<td>52</td>
</tr>
<tr>
<td>VerteCore Technologies</td>
<td>53</td>
</tr>
<tr>
<td>Voyager Biomedical</td>
<td>54</td>
</tr>
<tr>
<td>Zebra Medical Technologies</td>
<td>55</td>
</tr>
</tbody>
</table>

---

Welcome to the MedTech Conference powered by AdvaMed.

Thank you for joining us for the MedTech Innovator Showcase, a series of 11 interactive sessions each featuring four or five companies under a common technology theme.
MedTech Innovator Thanks Our Sponsors & Scholarship Supporters!

MedTech Innovator was Founded with Support from

[Logos of sponsors]

Additional Support is Provided by

[Logos of additional sponsors]

The Showcase is Brought to You by

[Logos of platinum sponsors]

Showcase Scholarships are Supported by

[Logos of scholarship sponsors]

For more information on sponsorships, please contact Ashley McMaster at ashley@medtechinnovator.org
# MedTech Innovator Showcase Schedule

**Tuesday, September 26**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10 - 9:50 AM</td>
<td>In Vitro Diagnostics</td>
<td>Jennifer Paine, Executive Vice President, Worldwide Quality, Regulatory &amp; Compliance, Ortho Clinical Diagnostics</td>
</tr>
<tr>
<td>9:55 - 10:35 AM</td>
<td>Health Care IT &amp; Digital Health</td>
<td>Tina Moen, PharmD, Deputy Chief Health Officer, IBM Watson Health</td>
</tr>
<tr>
<td>10:45 - 11:35 AM</td>
<td>Orthopedic</td>
<td>Todd Harrington, Vice President, Strategic Development &amp; Professional Affairs, Stryker</td>
</tr>
<tr>
<td>11:40 - 12:20 PM</td>
<td>Wound Healing &amp; Dermatology</td>
<td>Rob Albert, Senior VP &amp; Chief Marketing Officer, B. Braun Medical</td>
</tr>
<tr>
<td>2:10 - 2:50 PM</td>
<td>Therapeutic Delivery &amp; Dosing</td>
<td>Jordan Tuttle, Vice President, Strategic Investments, BTG</td>
</tr>
<tr>
<td>2:55 - 3:45 PM</td>
<td>Vascular &amp; Neurovascular</td>
<td>George Serafin, National Managing Principal, Healthcare &amp; Life Sciences, Grant Thornton</td>
</tr>
</tbody>
</table>

### Day Zero Diagnostics
- 17 2Morrow
- 7 Evoke Medical
- 20 Harbor MedTech

### Genomic Expression
- 24 GreenLight Medical
- 25 MYOVUE
- 34 Landsdowne Labs

### NovaGray
- 37 Redox
- 47 Osso VR
- 39 MetaOptima

### OncoTab
- 38 RxAssurance
- 49 VerteCore Technologies
- 53 Zebra Medical Technologies

### Moderators
- Jennifer Paine, Executive Vice President, Worldwide Quality, Regulatory & Compliance, Ortho Clinical Diagnostics
- Tina Moen, PharmD, Deputy Chief Health Officer, IBM Watson Health
- Todd Harrington, Vice President, Strategic Development & Professional Affairs, Stryker
- Rob Albert, Senior VP & Chief Marketing Officer, B. Braun Medical
- Jordan Tuttle, Vice President, Strategic Investments, BTG
- George Serafin, National Managing Principal, Healthcare & Life Sciences, Grant Thornton

### Entrepreneurs
- 2Morrow
- Evoke Medical
- Harbor MedTech
- Abreos Biosciences
- HemaFlo Therapeutics
- GreenLight Medical
- MYOVUE
- Landsdowne Labs
- Encellin
- Myonic
- Redox
- Osso VR
- MetaOptima
- Otricath
- Nexeon MedSystems
- RxAssurance
- VerteCore Technologies
- Zebra Medical Technologies
- PharmaJet
- PeriCor
- Voyager Biomedical
# MedTech Innovator Showcase Schedule

## Wednesday, September 27

<table>
<thead>
<tr>
<th>Segment</th>
<th>Session</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonology &amp; Critical Care</td>
<td>8:10 - 9:00 AM</td>
<td>Gabriele Brambilla, Chief Executive Officer, Alira Health</td>
</tr>
<tr>
<td>Consumer Health</td>
<td>9:05 - 9:45 AM</td>
<td>Colin Lawlor, Chief Executive Officer, SleepScore Labs</td>
</tr>
<tr>
<td>Surgical Tools &amp; Planning</td>
<td>9:50 - 10:40 AM</td>
<td>Amy Lencove, Director, Baxter Ventures</td>
</tr>
<tr>
<td>Advanced Imaging Diagnostics</td>
<td>10:45 - 11:35 AM</td>
<td>K.C. Hasson, Ph.D., Senior Manager, Business Development &amp; Innovation, Canon BioMedical</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>11:40 - 12:30 PM</td>
<td>Julia Stubben, MBA, VP European Sales &amp; Marketing, CVRx</td>
</tr>
</tbody>
</table>

### Alignment

<table>
<thead>
<tr>
<th>Segment</th>
<th>Session</th>
<th>Moderator</th>
<th>Company Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonology &amp; Critical Care</td>
<td>8:10 - 9:00 AM</td>
<td>Gabriele</td>
<td>Aqueduct Critical Care</td>
<td>13</td>
</tr>
<tr>
<td>Consumer Health</td>
<td>9:05 - 9:45 AM</td>
<td>Colin</td>
<td>EBS Technologies</td>
<td>18</td>
</tr>
<tr>
<td>Surgical Tools &amp; Planning</td>
<td>9:50 - 10:40 AM</td>
<td>Amy</td>
<td>Allotrope Medical</td>
<td>12</td>
</tr>
<tr>
<td>Advanced Imaging Diagnostics</td>
<td>10:45 - 11:35 AM</td>
<td>K.C.</td>
<td>Arterys</td>
<td>14</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>11:40 - 12:30 PM</td>
<td>Julia</td>
<td>Access Vascular</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>mOm Incubators</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>palmm</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Eximis Surgical</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Avenda Health</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Centerline Biomedical</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alleviant Medical</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Revolutionary Medical Devices</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Patiency</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ExplORer Surgical</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genetesis</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nanowear</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Selio Medical</td>
<td>50</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tray Health</td>
<td>51</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Innoblative Designs</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M&amp;S Biotics</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Promaxo</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>VADovations</td>
<td>52</td>
</tr>
</tbody>
</table>
Clinically-tested, mobile behavior change platform for improving health & wellness

2Morrow integrates behavioral science, clinical trials, & user experience to deliver effective behavior change programs that actually work.

Based on Acceptance & Commitment Therapy (ACT), the core program was developed/tested over 6 yrs. w/ $10M in NIH funded R&D at Fred Hutch Cancer Research Center.

2Morrow Health – one proprietary platform, multiple programs for weight, stress, smoking & chronic pain.

Flagship product, SmartQuit, is the first smoking cessation app proven effective in clinical trials.

Two published clinical trials show SmartQuit increases a smoker’s chance of quitting 2-3x.

Large employer realized 5x more participants & 5x more quitters than their tele-coaching program w/ 50% of survey respondents reporting they are smoke-free.

**Significant Milestones**

- Two published clinical trials on app. 6 RCT on ACT for smoking cessation. ACT found to be 2X more effective for cessation.
- Clients: WA DOH, Wellness Platforms, Employers, Health Plans, Nonprofits.
- Raised $980K (angels, grants, & founders).

**Fundraising**

- Seeking $3M Seed.
Precision dosing of biologic drugs to maximize clinical outcomes & minimize side effects

- The Veritope™ platform is a proprietary reagent platform that enables clinicians to deliver personalized, precision dosing tailored to the individual needs of patients
- Veritopes™ measure levels of a given biologic or biosimilar drug in the blood & can be implemented in any immunoassay format for laboratory or point of care testing
- Extensive Veritope™ pipeline consisting of 19 Veritopes™ against marketed biologic drugs
- Veritope™ dose monitoring tests are unique personalized medicine tools that enhance biologic drugs by differentiating products in crowded markets, stratifying patients in clinical trials, & improving access to value-based reimbursement

Significant Milestones
US patent awarded protecting key IP
Custom services deals with pharma for biosimilar & antibody-drug conjugate targets
Advanced discussions with pharma for custom services & complementary diagnostics deals
Raised $2.3M to-date in equity funding

Fundraising
Seeking $8M Series A

Laboratory Near Patient Point of Care

Presenting in the
Therapeutic Delivery & Dosing Showcase
Tuesday September 26
2:10 pm - 2:50 pm

San Diego, CA

Bradley Messmer, PhD
Founder & CEO
bmessmer@abreosbio.com

Michael Little, PhD
VP BD

Laura Ruff, PhD
Director, R&D

William Yashar
Director, BD

Jessica Pfeilsticker, PhD
Director, Assay Development

www.abreos.com
Novel bulk-hydrophilic biomaterial that reduces thrombotic risk & complications

- Access Vascular is developing a platform of venous access devices using novel bulk-hydrophilic biomaterial technology that prevents blood component accumulation (thrombus).

- Proprietary biomaterial is not recognized by the body as foreign material & therefore does not trigger the body’s thrombotic response, starting a cascade of events that leads to catheter occlusion & bacterial colonization. Net result is improved procedural efficiencies, higher quality of care, & improved reimbursement.

- Flagship device is the HydroPICC™, a peripherally inserted central catheter.

- In testing, HydroPICC™ showed up to 98% reduction in thrombus accumulation demonstrating the potential for superior clinical outcomes with lower associated healthcare costs when compared to existing technologies.

- Robust pipeline includes midlines, dialysis catheters & ports.

**Significant Milestones**
- Provisional patent filed
- Fully-functional prototype built
- FDA 510(k) pathway confirmed for HydroPICC™
- Manufacturing facility build out in progress

**Funding**
Access Vascular has secured private financing, with sufficient funding to support FDA submission for HydroPICC™ & expansion of manufacturing capabilities.

---

Presenting in the Cardiovascular Showcase

- **Wednesday, September 27**
- **11:40 am - 12:30 pm**
Medical device specifically designed to treat preeclampsia

- Specific treatment for preeclampsia, utilizing a proprietary Targeted Apheresis Column for Preeclampsia (TAC-PE)
- Patented technology selectively targets the removal of blood components associated with the symptoms of preeclampsia, preserving natural & vital blood components
- Aims to relieve symptoms of preeclampsia, such as high blood pressure, so pregnancy can be safely prolonged
- Extending pregnancy duration reduces the risk of lifelong disabilities associated with prematurity, decreases healthcare costs, & helps mothers & babies survive
- Easy integration into existing therapeutic apheresis devices
- Enables a fundamental shift in how patient care is delivered – from critical care & NICU to preventive care in the maternity ward

Significant Milestones
- US patent granted
- Proprietary binding agent for sFlt-1 developed
- Commercial prototype under development
- Collaborating with University of New Mexico for clinical observational study

Fundraising
- Seeking $5M Series A
Minimally invasive device to treat heart failure through reduction of elevated left atrial pressure

- Transcatheter device that relieves pressure buildup within the left atrium, which is the key driver of heart failure symptoms & hospitalizations
- Single use disposable device
- Simple, low-risk cath lab procedure
- Target population: Patients w/ mild, moderate, & severe heart failure
- $5B total addressable market (based on $500K eligible patients annually in US & EU)
- Designed to relieve patient symptoms, improve quality of life, & reduce hospital readmissions due to heart failure exacerbations

**Significant Milestones**
- Provisional patents filed (conversion Q1 2018)
- Multiple working prototypes built & successfully tested in swine models
- Preclinical pilot study initiated Q3 2017 at Houston Methodist Hospital

**Fundraising**
- Seeking $1.5M Seed

---

**ALLEVIANANT**

Houston, TX

Jacob Kriegel, MD  
Co-Founder & CEO  
jacob.kriegel@alleviantmedical.com

Avni Patel  
Co-Founder & COO

Alex Arevalos, PhD  
Co-Founder & CTO

Albertien Greijdanus  
Co-Founder & CCO

Presenting in the Cardiovascular Showcase  
Wednesday  
September 27  
11:40 am - 12:30 pm
Innovative surgical solutions that improve patient outcomes by reducing procedure time & injury risk

- Flagship device is StimSite: A handheld, single use, battery powered device that quickly, easily & safely allows the surgeon to identify the ureter during minimally invasive surgery
- StimSite is applicable in over 3M cases in the US & may eliminate additional procedures, increase OR throughput, decrease injury risk & decrease non-reimbursed surgical costs
- No pre-submission clinicals projected to be required, & 510(k) clearance for StimSite anticipated Q4 2018 with early market entry Q1 2019
- Platform technology with applications in esophageal, gastric, small intestine & colonic disease states & surgical procedures
- Technology is easily integrated into existing electrosurgical devices & systems

Significant Milestones
8 patents filed in US, EU, & China protecting system & methods for ureter detection & smooth muscle stimulation via electrical stimulation (with expanded clinical & technologic applications)
Large animal studies performed showing efficacy in thickened/scarred as well as normal tissues
Selected as top innovation by panel of surgeons during the 2017 SAGES conference (one of the largest minimally invasive surgical organizations in the world)

Fundraising
Seeking $3M Series A

www.allotropemed.com
Transforming the way patients with temporary external CSF drains are managed

- The Smart External Drain is an external self-adjusting CSF drainage system designed to eliminate continuous manual adjustments & interventions by trained nursing staff
- Patient specific settings & alarm parameters
- Reduces number of adjustments required of critical care nurses
- Potential to transfer otherwise healthy patients from expensive critical care to step-down care
- Patient complications & co-morbidities associated with incorrect adjustments or inadvertent patient movements may be reduced enhancing patient safety

Significant Milestones
- 1 patent granted, 16 patents filed
- 510(k) clearance obtained in Q4 2016
- Special 510(k) Q2 2017 software upgrade
- Marketing study with 10 patients Q3 2017

Fundraising
- Seeking $6M Series B

Presenting in the Pulmonology & Critical Care Showcase
- Tuesday, September 27
- 8:10 am - 9:00 am
Intelligent cloud supercomputing platform for medical imaging analysis

- Advanced software platform for medical image interpretation, combining cloud supercomputing & AI to provide doctors with the information they need to make confident care decisions
- Apps enable physicians with speed, accuracy, & the power of data-driven diagnoses
- First AI product contours cardiac anatomy as accurately as experts, but in 15-20 secs. instead of the 45-60 mins. required to do it manually
- 4D Flow scan is far more comprehensive vs. traditional methods, & is ~$200 less expensive
- Significant market traction with 10K+ patients scanned at 45+ active sites
- Future plans include expanding product offerings to assist radiologists in the detection, identification, measurement & tracking of lesions associated with different cancers

Significant Milestones
Received first ever FDA clearance, CE mark & Health Canada clearance for a Cloud/AI product
Cloud/AI platform FDA cleared Q1 2017
Established partnerships w/ Siemens & GE

Fundraising
Seeking $25M Series B

San Francisco, CA

Fabien Beckers, PhD
Co-Founder & CEO
fabien@arterys.com

John Axerio-Cilies, PhD
Co-Founder & COO

Albert Hsiao, MD, PhD
Medical Co-Founder

Shrevas Vasanawala, MD, PhD
Medical Co-Founder

Presenting in the Advanced Imaging Diagnostics Showcase
Wednesday September 27
10:45 am - 11:35 am

arterys.com
Image-guided laser ablation to treat prostate cancer in a doctor's office

- Focal laser ablation, proprietary sensor enabling in-office treatment
- Integrated treatment planning using machine learning
- Outpatient procedure
- Backed by peer-reviewed science
- Market opportunity: 60-80K men/year in the US; $4B

Significant Milestones
Feasibility study (10 patients) at UCLA completed in Q3 2016
All patients:
- Minimal anesthesia required
- Successful ablation demonstrated
- No incontinence or loss of sexual function

Fundraising
Seeking $2M Seed

Los Angeles, CA

Leonard Marks, MD
Chief Medical Officer

Shyam Natarajan, PhD
President
shyam@avendahealth.com

Brittany Berry-Pusey, PhD
VP BD & Strategy

Presenting in the Advanced Imaging Diagnostics Showcase
Wednesday September 27
10:45 am - 11:35 am

Targeted Tumor Ablation “The Male Lumpectomy”

www.avendahealth.com
3D visualization & navigation, predictive analytics & training for minimally-invasive procedures

- IOPS™ (Intra-Operative Positioning System) delivers three-dimensional visualization & real-time navigation minimizing exposure to high-dosage radiation & toxic contrast dyes
  
  Benefit: Increase patient & surgeon safety

- IOPS’ mathematical anatomical modeling capabilities would provide predictive vessel motion & deformation renderings enabling surgeons & practitioners to better prepare for & react during each case, improving patient outcomes
  
  Benefit: Reduce costs per case while improving OR utilization rates

- Will address multiple markets, including peripheral artery disease, bronchoscopy, carotid aneurysm, cerebral aneurysm, electrophysiology, endovascular aortic repair, & coronary intervention & stenting
  
  Benefit: A platform technology to address 4+ million cases annually

Significant Milestones
Raised $11.7M to date (Cleveland Clinic, G2 Venture Group, & private investors)

Fundraising
Seeking $12-17M Series B

Navigating a catheter (arrow) using fluoroscopy (left) versus IOPS (right). Actual clinical images from same patient at same moment in time.

Presenting in the Advanced Imaging Diagnostics Showcase
Wednesday, September 27
10:45 am - 11:35 am

www.centerlinebiomedical.com
Whole genome sequencing & machine learning to rapidly diagnose & treat serious infections

- DZD is developing a new class of diagnostic that enables physicians to start targeted antibiotics within hours rather than days
- DZD works directly from clinical samples, obviating the need for culture, & utilizes the whole genome sequencing data as input into a machine learning algorithm to predict antibiotic resistance quickly & comprehensively
- Faster diagnosis & resistance profiling leads to faster, more effective treatment which can significantly decrease mortality & cost.
- DZD enables reduced use of broad spectrum antibiotics, which can be expensive, exposes patients to significant toxicity, encourages further resistance & has become increasingly ineffective.
- Machine learning algorithm learns from a large training database initially built w/ 30,000 samples from Mass General Hospital
- Initially targeting application in sepsis diagnosis & treatment

Significant Milestones
Developed proof of concept prototype for each component of integrated system
Signed exclusive license for commercial use of database used in algorithm development

Funding
Raised $3.5M Seed

Boston, MA

Jong Lee, MBA
President & CEO
jong@dayzerodiagnostics.com

Doug Kwon, MD, PhD
Clinical Lead

Melis Anahtar, MD, PhD
Biomedical Lead

Miriam Huntley, PhD
Genomics Lead

Dougal MacLaurin, PhD
Software Lead

Presenting in the
In Vitro Diagnostics Showcase
Tuesday September 26
9:10 am - 9:50 am

www.dayzerodiagnostics.com
Non-invasive optic nerve stimulation device for restoring vision

- **EYETRONIC** is a non-invasive ONS therapy for the treatment of visual field defects caused by disorders of the optic nerve, such as glaucoma, eye infarct, trauma or stroke.
- Consists of stimulation goggles, EEG cap, patient unit & supervisor unit.
- Therapy carried out in the doctor’s office in 10 sessions of 60-90 minutes held on 10 consecutive working days.
- Patient adaptable for individualized therapy.
- 300 patients have been treated with 95%+ satisfaction rate & no observed SAEs.

**Significant Milestones**
- Received CE mark
- Secured portfolio of 7 patent families
- Completed Class Ib (RCT) trials showing efficacy & safety

**Fundraising**
- Seeking €10M Series D

Presenting in the Consumer Health Showcase
- Wednesday September 27
- 9:05 am - 9:45 am

www.eyetronic.com
Implantable ultra thin-film cell delivery technology for diabetes management

- Implantable cell delivery technology that protects insulin-secreting cells from the immune system
- Provides access to cell therapy solutions for Type 1 diabetics without immunosuppression
- Demonstrated proof of concept:
  - Detects glucose & secretes insulin appropriately
  - Neovascularization without fibrosis in vivo
  - Immunoprotection in an allotransplant model in vivo
- Provides a long-term auto-regulation therapeutic solution for Type 1 diabetes

**Significant Milestones**
- Utility patent filed Q1 2016
- Pre-IND meeting with FDA Q1 2018
- First in man study initiated Q3 2018 to demonstrate safety & immunoprotection
- Enable device manufacturing validation
- To date: $6.6M through grants from sources including NSF, JDRF, Sandler Foundation, Roger Foundation, & Whitaker Foundation

**Fundraising**
- Seeking $4M Series A

---

**Presenting in the**

- **Therapeutic Delivery & Dosing Showcase**
- **Tuesday, September 26**
- **2:10 pm - 2:50 pm**

---

**Crystal Nyitray, PhD**
Founder, Inventor, & CEO
[crystal@encellin.com](mailto:crystal@encellin.com)

**Grace Wei, PhD**
Founder & COO

**Ronald Martell**
Executive Chairman

**Tejal Desai, PhD**
Advisor & Inventor

**Vern Norviel**
IP, Council at WSGR

---

**San Francisco, CA**

---

[www.encellin.com](http://www.encellin.com)
Biomechanically powered, osteoinductive spinal fusion implant

- Spinal interbody fusion implant with built in electrical stimulation properties to improve bone healing
  - Reduces reoperation due to failed fusion
  - Quicker, more robust fusion
  - Addresses difficult to fuse population
- Implant mimics natural healing properties of bone (i.e. Wolff’s Law)
- Passively powered device, which does not require a battery
- Eliminates the need for expensive & unproven adjunct therapies such as BMP, other biologics, or external electrical stimulators
- Fusion Diagnostic Capabilities – device can externally indicate fusion progress (secondary revenue stream)
- Other bone healing applications outside of spine

**Significant Milestones**
- Patents pending for platform material technology
- Prototype & proof of concept animal study completed – advanced bone healing demonstrated
- Awarded $225K NIH STTR Phase I Grant

**Fundraising**
- Seeking $750K Seed
Digital surgical playbook to improve intraoperative communication & efficiency

• An interactive platform that builds on each team member’s procedural knowledge to improve intraoperative communication, awareness, & patient safety

• Provides surgical team members with a digital, role-specific reference in real-time, complete with pictures & videos of materials, room setups, patient positioning, & technical steps of the case

• Analytics component may be used to improve hospital efficiency by tracking OR team performance & optimizing resource management

• Demonstrated to reduce intraoperative disruptions arising from missing or incorrect instruments, reduce set-up time, & reduce wasted disposables

Significant Milestones
5 staged implementations at large academic & community medical centers around the US; several medical device & durable medical equipment partners & customers

Funding
Closed $3.3M Series A Q3 2017, led by Aphelion Capital

Presenting in the Surgical Tools & Planning Showcase Wednesday September 27 9:50 am - 10:40 am
Device for the safe, fast removal of large specimens during minimally invasive surgeries

- XCor allows surgeons to quickly & easily remove large specimens through small incisions while creating clean cut segments more adequate for pathology
- Solves current problems associated w/ morcellators including preventing the spread of unknown cancers in a patient’s abdomen
- Reduces procedure time from ~45 mins. to 5 mins. saving valuable physician & operating room time
- Patients benefit from shorter anesthesia times & smaller incisions that reduce pain, recovery time, & post-operative complications
- Potential to expand into other gynecologic, general, hepatobiliary, pediatric, & thoracic surgeries

Significant Milestones
Completed proof of concept w/ positive feedback from 26 surgeons, all of whom will adopt XCor once FDA approved

Fundraising
Seeking $4.5M Series A
CardioFlux passively, & w/out patient contact, measures the cardiac-generated magnetic fields emanating from a patient's chest.

Portable technology that can be wheeled to the bedside of the emergency room.

Sensitivity & specificity of the system to ischemia in patients w/ unstable angina is comparable to stress imaging, yet can be performed in seconds & w/out patient risk.

CardioFlux analytical tools showed a 79% improvement over ECG, 40% improvement over troponin in detecting ischemia, & demonstrated competitiveness w/ stress echocardiography.

Significant Milestones
Completed 30 patient retrospective study at the Mayo Clinic
NVIDIA Social Impact Award Winner ($375K)

Fundraising
Seeking $7M Series A

Presenting in the Advanced Imaging Diagnostics Showcase Wednesday September 27 10:45 am - 11:35 am
RNA-sequencing based technology for identifying the appropriate therapy for cancer patients

- Diagnostic service linking sequencing to known therapies & clinical trial options, maximizing outcomes
- Genetic driver identification allows earlier diagnosis & truly individualized treatment planning based on scientific outcomes across the treatment spectrum
- Cloud-based solution generating a personalized, actionable report for each tumor based on its gene expression profile
- Minimizes side effects from inappropriate, standardized treatment regimens & generalized dosing

**Significant Milestones**
Established partnership with OvaCure.org
Diagnostic partner for the $32M Genome Denmark project
Top 10 in XTC 2015

**Fundraising**
Seeking $10M Series A
Cloud-based software to streamline hospital value analysis of new medical technology

Nashville, TN

Austin Dirks
Founder & CEO
austin@greenlightmedical.com

Troy Kyle
COO & Director

Stephen Saine
CTO

• All-in-one software to connect medical suppliers with hospitals for the introduction, review, & approval of new medical technology within hospital value analysis

• Provides workflow solution, project management, & data repository for hospitals

• Provides standardization of new product request process, transparency to sales cycle, & access to key stakeholders for medical device suppliers

• Cloud-based automation has enabled a 35-day average from submission to decision

• Deployed in 24 hospitals, 1 ambulatory surgery center, with 1000+ hospital users & 600+ medical device sales reps representing 300+ medical device companies

• Signing deal w/ large IDN to add >100 hospitals to portal

• Announcing release of Corporate portal for medical device manufacturers

Significant Milestones
Backed by Jumpstart Foundry, TMCx, & Healthbox
Featured in Forbes & Google Demo Day
RESI Innovation Challenge 2nd place winner
Raised $1.2M to date from family, friends, physicians, & angel investors

Fundraising
Seeking $3-4M Series A

Presenting in the Health Care IT & Digital Health Showcase Tuesday September 26 9:55 am - 10:35 am

www.greenlightmedical.com
Next generation skin substitute for use in managing complex skin wounds

- Independent study by the Ohio State University Regenerative Medicine Center discovered that our patented BriDGE® technology actively recruits the patient’s own growth factors to dramatically accelerate healing while preventing infections & inhibiting scar formation
- Two products FDA approved & CE Marked, with five products in near-term pipeline targeting orthobiologics, general & plastic surgery
- Clinical studies of first product, Architect®, show that it heals complex wounds twice as fast as competitive products with just one application, improving patient outcomes at a much lower cost to the healthcare system
- Next product, EPMatrix™, will be first biologic surgical mesh to bioactively accelerate healing & prevent infections in surgical repairs of torn ligaments & tendons

Significant Milestones
Received FDA approval & CE Mark on Architect Stabilized Collagen Matrix

Fundraising
Seeking up to $15M Series C
Treating AKI with a Drag-reducing polymer that doubles blood flow without increasing blood pressure

- Acute kidney injury (AKI) is an unintended consequence of hospitalization that impacts 7.0 million ICU patients a year in the US, resulting in 3.2 million severe cases & 790,000 deaths, & adds $34,000 in incremental costs to treat each severe case.

- NephroFlow® is formulated with drag-reducing polymer (DRP) to dramatically increase blood flow in patients without increasing the strain on their heart.

- Single administration produced a statistically significant improvement in kidney function within 24 hours in animal studies & cut their death rate in half.

- Product is stable at room temperature, easy to administer through IV bag, & composed solely of FDA approved excipients.

Significant Milestones
- Secured FDA designation as a device
- Pilot animal studies completed
- Patents issued covering core technology
- Raised $380K to date

Fundraising
- Seeking $8M Series A to complete First-in-Human clinical study

Carlsbad, CA

Michael Martino
President & CEO

Dale Peterson, PhD
CSO
dpeterson@hemaflo.com

Presenting in the
Vascular & Neurovascular Showcase
Tuesday September 26
2:55 pm - 3:45 pm
Intelligent, deep-learning device for personalized ablative cancer treatment

- SIRA is a saline-assisted intra-cavitary radiofrequency ablation device for the treatment of breast cancer & other soft-tissue diseases
- SIRA-S technology automatically senses real-time ablation status using deep-learning (artificial intelligence) in three-dimensions & creates accurate custom treatment geometries
- Innoblative’s devices destroy residual cancer in minutes & in one treatment
- The treatment aims to reduce reoperations, eliminate the need for radiation therapy in early stage patients, & decrease the direct & indirect costs of cancer treatment
- Proof-of-concept clinical trial complete at UAMS & subsequent studies underway at Northwestern University & expanding to multiple centers

Significant Milestones
Design freeze completed
Usability study completed
Proof of concept clinical study completed
FDA pre-submission meeting completed
Winner of M2D2 $100K Challenge 2016
Raised $5M+ to date from angel investors

Fundraising
Seeking Series A

Tyler Wanke  
Co-Founder & CEO  
tyler@innoblative.com

Bob Rioux  
CTO & COO

Roberta Lee, MD  
CMO

Anna Lisa Somera  
VP Reg. Quality & Clinical

Victor Simoes  
VP Finance & Strategy

Presenting in the Surgical Tools & Planning Showcase  
Wednesday  
September 27  
9:50 am - 10:40 am
Quick release medical tape designed for use on patients with fragile skin

- Uses standard adhesives configured in novel ways to provide a medical tape that offers secure adhesion while being quickly & easily removable
- Adhesive product minimizes skin tearing for patients with fragile skin such as premature infants & elderly
- Improves wound management & reduces infection risk

Significant Milestones
Exclusive option in place to license technology from Brigham & Women’s Hospital
Children's National Hospital Pediatric Device Innovation Competition Winner ($25K)

Fundraising
Seeking $1.1M Seed
Combining RFID technology & AI to create more efficient, effective, & safer surgical procedures

- Currently, 14% of operative time is spent counting surgical sponges, with 1 in 8 surgical procedures having a counting discrepancy due to this manual process; worse yet, less than 20% of surgical instruments are utilized during the course of the procedures
- Combined, this costs hospitals millions of dollars in costs & lost productivity
- M&S Biotics addresses this problem with the Biotic Integration System, which automates the surgical counting process while providing downstream analytics to supply chain to create more uniform & standard surgical sets
- Biotic (RFID) system is the first autonomous system with the ability to detect, track, count, & locate surgical items in real-time
- Biotic Insight platform provides data analytics regarding instrument utilization

Significant Milestones
Partnerships with Stony Brook University School of Medicine & Baylor College of Medicine, Startup Health, & TMCx
Signed LOI’s with two hospital systems
Signed pilot agreements with Highland Surgical Center & Southampton Hospital
Pending sale with Seton Medical Center at University of Texas (Austin)

Fundraising
Seeking $1M Seed
DermEngine: intelligent data-driven clinical platform for diagnostics & therapeutics in dermatology

- More than 40% of primary care visits are skin related & skin cancer is the most common cancer that costs over $10B/year in unnecessary procedures due to lack of training for PCPs
- DermEngine is a cloud-based dermatology platform that offers efficient data acquisition & advanced clinical decision support tools for diagnostics & therapeutics
- Computer Vision & Machine Learning algorithms unlock the power of data to offer more accurate & efficient care while saving costs for payers & providers
- DermEngine’s Artificial Intelligence is vertically implemented across all stakeholders including patients, PCPs, dermatologists, pathologists, oncologists & surgeons & becomes more intelligent by their everyday use
- DermEngine integrates with EMRs, Practice Management Systems & Lab Information Systems to offer clinical intelligence & enhance the workflow efficiency for clinicians

Significant Milestones
DermEngine launched in 2016
DermEngine AI launched in Q1 2017
Established partnerships with clinic chains in 2016
Created the largest database for skin cancer in 2017
Closed over $1M in sales in 2017

Fundraising
Seeking $5M Series A

Presenting in the Dermatology & Wound Healing Showcase  Tuesday September 26 11:40 am - 12:20 pm

Vancouver, Canada

Maryam Sadeghi, PhD
Co-Founder & CEO
maryam@metaoptima.com

Majid Razmara, PhD
Co-Founder & CTO

Sean Hodgins
CFO

www.metaoptima.com
Portable, cost-effective incubator for preventing neonatal complications

- Inflatable incubator increases access to care for premature & hypothermic babies worldwide
- Prevents complications associated w/ delayed thermoregulation such as tissue hypoxia, neurologic damage, & transient hyperglycemia which contribute to prolonged stay in the NICU
- Presents a 90% cost savings over conventional incubators & can be compacted to a fraction of the size at less than 10% of the weight
- Naturally insulative which reduces power use between 80-95% lower than that of a conventional incubator
- Innovative design supports easy maintenance & repair

Significant Milestones
Established partnership w/ Morgan Innovation & Technology
MassChallenge UK Diamond Prize Winner (£50K)
Established clinical partnership w/ world renowned NGO

Fundraising
Seeking £5-10M Series A

Surrey, United Kingdom

James Roberts
Co-Founder
jroberts@momincubators.com

Matthew Khoory
Co-Founder

Presenting in the
Pulmonology & Critical Care Showcase
Wednesday September 27
8:10 am - 9:00 am

www.momincubators.com
Wearable device for allowing paralyzed users to regain control of their muscles

- Through an established partnership with Emotiv, Myonic’s technology utilizes an intuitive Brain Computer Interface (BCI) that allows patients to easily command their muscles.

- This technology is non-invasive & safe to use for extended periods of time.

- Myonic Move can be fully controlled with nothing more than the user’s thoughts & simple head motions.

- A patient can train the device to read their thoughts with the BCI in under 15 minutes.

- The device outputs a safe electrical impulse to contract the user’s muscles.

- The electrodes are embedded within an easy-to-use sleeve which allows movement of the thumb, four fingers, & elbow to assist in performing basic everyday tasks.

**Presenting in the**

**Vascular & Neurovascular Showcase**

**Tuesday September 26**

**2:55 pm - 3:45 pm**

**Significant Milestones**

- Alumni of the Boomtown Accelerator
- Voted the Top Hardware Startup at TechCrunch Disrupt NY 2017
- Completed regulatory assessment
- Launching beta test Q4 2017
- Direct-to-consumer sales Q2 2019

**Fundraising**

- Seeking $1.5M Seed
Pressure monitoring device used to control risks of developing Acute Compartment Syndrome (ACS)

• Competitive Advantages
  ▪ More accurate
  ▪ Continuous monitoring
  ▪ Wireless & cloud based

• Simple Single Use Device
  ▪ No training needed, simple like an IV Class II, 510(k) device
  ▪ Existing reimbursement code

• Economic Value
  ▪ MYOVUE pressure monitoring system allows earlier detection of ACS resulting in:
    o Easier & faster intervention for physicians
    o Saves OR time for hospitals
    o Better outcome for patient
    o Significant economic value for payers

Significant Milestones
Patents filed covering MEMS, device, & insertion method
Pilot animal study completed demonstrating device validity
Started Canadian clinical trial
Clear regulatory pathway

Fundraising
Seeking $3.5M Seed, of which $500k remaining

Montréal, Canada

Charles Allan  
Co-Founder & CEO  
charles.allan@nxtsens.com

Ed Harvey, MD  
Co-Founder & CMO

George Xereas, PhD  
Co-Founder & CTO

Vamsy Chodavarapu, PhD  
Co-Founder & VP Research

Presenting in the Orthopedic Showcase  
Tuesday September 26  
10:45 am - 11:35 am

www.myovue.com
Patented cloth-based nanosensor technology captures & transmits medical-grade electrophysiological, biochemical, hemodynamic, audio/phonography & actigraphy measurements despite presence of hair, sweat, or other moisture

SimpleSense is an undergarment used for remote monitoring of CHF by capturing & algorithmically scoring ECG, heart rate variability, respiratory rate, impedance cardiography, thoracic impedance, cardio-phonography & actigraphy

SimpleSense sends care management teams a daily score alerting physicians & nursing staff of decompensating Heart Failure weeks in advance of a hospitalizing event, enabling teams to intervene during normal office hours

SimpleSense endpoints are supported by HeartLogic/MultiSENSE trials, which showed 75% success rate in heart failure alerts >14 days in advance of an event when measuring the same metrics

Significant Milestones
Received Class II FDA approval for nanosensors, mobile application & physician portal capturing & transmitting multichannel ECG, HRV & RR
SimpleSense Clinical Data w/ CHF patients

Fundraising
Seeking $8-9M Series A
Closed-loop neurostimulation device for relief of chronic neurological disease

- Synapse™ system is a next-generation Deep Brain Stimulation (DBS) technology to treat Parkinson’s Disease
- Precision, closed-loop neuromodulation with recording capabilities helps monitor disease progression & therapy efficacy
- Smart technology eliminates the need for an iterative approach to pulse setting optimization & facilitates expedited, patient-specific programming adaptable to demand over time
- Requires a single surgery to install versus the standard of care, which requires multiple surgeries to update & reprogram

Significant Milestones
- Acquired 100 patents from Siemens & Medtronic
- Raised $4.3M private capital & $9M non-dilutive funding

Fundraising
- Received ticker symbol (OTCQB: NXNN) from FINRA & trading

Presenting in the Vascular & Neurovascular Showcase
- Tuesday, September 26
- 2:55 pm - 3:45 pm

Will Rosellini
Chairman & CEO
will@nexeonmed.com

Brian Blischak
President & CCO

Chris Miller
CFO
Biomarker-based test to assess patients' sensitivity for personalizing radiotherapy

• First predictive test of its kind allowing radiation oncologists to tailor treatment to patients
• Identifies, using a single blood sample, patients that will develop severe complications after radiotherapy as well as patients that are eligible for hypofractionated regimen
• Clinically validated by a 10-year prospective multicenter clinical trial w/ 489 breast cancer patients
• Ongoing prospective multicenter trials to validate tests for prostate & lung cancer
• Up to 30% savings on reducing treatment length for low-risk patients & additional savings on avoiding complications

Significant Milestones
CE Marked Q1 2016 (breast cancer test)
First patient out-of-pocket purchase in Q4 2016
Patents filed in 2013 & 2016

Fundraising
Seeking €3M Seed
Blood test to enable breast cancer detection two years before mammography

- Agkura™ Personal Score (APS) uses a patented monoclonal antibody to detect cancer in patients, especially those with dense breast tissue
- Monitors circulating levels of a tumor specific protein that is present in 95% of breast cancer tissue, across all breast cancer subtypes
- As a supplement to mammography, APS can:
  - Double cancer detection rate
  - Reduce interval cancers by 50%
- May lead to earlier stage diagnosis of breast cancer up to 2 years earlier compared to mammography alone
- Invited by Department of Defense to propose multi-site clinical trial proposal

Significant Milestones
9 US & International patents issued
3 National Cancer Institute Awards ($830K)
Raised ~$1.8M to-date from angel investors

Fundraising
 Seeking $15M Series A

Presenting in the In Vitro Diagnostics Showcase Tuesday September 26 9:10 am - 9:50 am
Hands-on medical device training platform using virtual reality

- Medical device training platform designed to increase efficiency of surgical training as well as adoption of new medical devices in highly realistic virtual environment
- Current paradigm of cadaver courses are $300-350K each for a large scale course & are highly inefficient, with 4-6 month gap on average between course & inpatient use
- With Osso VR, physicians can rapidly achieve proficiency with new medical technology & regain the autonomy to decide which devices provide the best value for their patients
- Can also be used for device rep training. High rep turnover & numbers leads to massive onboarding cost (~$3.4B/yr)
- Osso VR decreases the cost of customer & rep training, while providing a convenient & repeatable option that will increase the ROI on training dollars spent through higher conversion rates & better patient outcomes

Significant Milestones
- Working with Top 5 Orthopaedic Device Company
- DoE EdSim Challenge Finalist 2017
- Completed clinical validation study at UCLA demonstrating 2x improvement in surgical skill

Fundraising
- Recently closed $2M Seed (led by SignalFire)
Catheter system for the precision delivery of therapeutic agents to treat solid tumors

Houston, TX

Ray Calderon, MD
Founder

Delores Calderon
Co-Founder & COO

Caroline Negley
VP Business Development
cnegley@otricath.com

Otricath is a closed loop catheter delivery system

- Enables more control, predictability, & safe therapeutic benefit in application of certain therapies, including chemotherapy & immunotherapies
- Prevents harmful systemic side effects by utilizing a venous-venous delivery technique
- Infuse → Monitor → Withdraw technique
- Transducer with pressure monitoring capability
- Predictable, reliable, & repeatable delivery supported by in-vivo porcine studies
- Real-time analysis during procedure
- Right dose, right place, right time

Significant Milestones

In vivo preclinical studies
Alpha prototype
$35K 2nd Place Winner at Texas A&M New Ventures Competition 2017
NSF regional I-Corps program 2017
TMCx Medical Device Accelerator 2016

Fundraising

Seeking $1.5M Seed, of which $750K remaining

Presenting in the Therapeutic Delivery & Dosing Showcase Tuesday September 26 2:10 pm - 2:50 pm

www.otricath.com
Convenient at-home treatment for excessive sweating of the hands (palmar hyperhidrosis)

- ‘Electrical antiperspirant’ in a glove to treat excessive sweating of the hands
- Wear for 30 minutes once weekly to keep hands dry
- Current standards of care (e.g., antiperspirants, systemic drugs, botox injections) are ineffective, invasive, or expensive
- Clinically tested in 9 patients, documenting a very significant reduction in sweat levels (65% on average), with reported meaningful improvement in daily quality of life

Significant Milestones
- Completed successful clinical study at Stanford University
- Validated patient willingness-to-pay
- Portfolio company of the Fogarty Institute for Innovation & StartX

Fundraising
- Seeking $1.5M Seed

Sweat staining before/after (demonstration on portion of hand only)
Blockchain-secured solution for connecting patients to their health information

- Decentralized population health management tool & patient portal secured by blockchain
- Assists healthcare organizations in improving outcomes via automated chronic care plans
- Streamlines coordination of care by centralizing complete patient history
- Eliminates risk of healthcare breaches through decentralized blockchain technology
- Patient engagement software capability

Significant Milestones
Two provisional patents filed
2000+ customer validation interviews completed with the aid of Colorado Permanente Medical Group

Funding
Raised $7.2M in Q2 2017 Token Sale

Presenting in the Consumer Health Showcase
Wednesday, September 27
9:05 am - 9:45 am
Access tool for percutaneous epicardial procedures to replace open-chest surgery

- PeriPath is designed specifically for the pediatric population & converts open chest surgery to a single, percutaneous incision procedure
- First multi-lumen tool for access of the pericardial space
- Provides direct visualization through a deflectable endoscope
- Eliminates the need for procedural fluoroscopy
- Accommodates 4mm endoscopes & any cardiac therapy up to 8mm
- Compatible with all commercial delivery tools for epicardial ablation, pacing, & defibrillation therapy
- Reduces collateral tissue damage, post surgery pain, & recovery time

**Significant Milestones**
Animal study in 15 infant piglets completed
National Capital Consortium: Pediatric Device Innovation 2016 Top 3 ($50K)
Clinical Translational Science Institute - Pediatric Innovation Fund Award Winner 2016 ($50K)
Completed pre-submission meeting with FDA & established 510(k) approval pathway
Received $175K philanthropic donation

**Fundraising**
Seeking $8-10M Series A

**Presenting in the**
Vascular & Neurovascular Showcase 2:55 pm - 3:45 pm

Charles Berul, MD
CEO

Axel Krieger, PhD
CTO

Bradley Clark, MD
CMO

Justin Opfermann, MS
Lead Engineer
jopferma@cnmc.org

PeriPath – A Single Site Access Tool
Safe, fast, & easy needle-free vaccine/biologic delivery system

- Needle-free vaccine delivery for intramuscular, subcutaneous, or intradermal use
- Lack of needle eliminates needle stick injuries & disease transmission
- Improves immune response of some vaccines & therapeutics
- Savings generated for each injection through dose sparing, dose efficiency, & elimination of sharps risk & disposal
- Completed largest needle-free vaccination study for influenza resulting in first ever FDA issued vaccine label change for PharmaJet as a method of administration (Stratis®)
- Pre-fillable syringe in development
- Fractional dose polio clinical confirmation by World Health Organization (WHO) demonstrating 60% less vaccine is superior in immune response (2 fractional doses fIPV/ID with PharmaJet Tropis® vs. 1 full dose IPV with needle/syringe)

Presenting in the Therapeutic Delivery & Dosing Showcase Tuesday September 26 2:10 pm - 2:50 pm

Significant Milestones
Several regulatory device & on label approvals for Stratis (IM/SC) device, including FDA, CE Mark, DCGI, WHO PQS & others
Stratis commercially launched Q4 2015 in US; Q1 2017 in India
Tropis intradermal device has CE Mark & is completing WHO PQS

Fundraising
Seeking $10M Series G

Ron Lowy
CEO

Jeffrey Jordan
CFO

Heather Potters
Chief BD Officer
heather.potters@pharmajet.com

Chris Cappello
COO

Golden, CO

www.pharmajet.com
Respiratory monitoring for the detection of opioid-induced respiratory depression

• PneuMotion combines respiratory rate & oxygen saturation into a single critical parameter, ensuring timely intervention & reduction of false alarms
• Respiratory acoustics & chest wall motion analysis provides sensitive & reliable airway obstruction detection
• Proprietary algorithm for the detection of obstructive sleep apnea
• Bluetooth & Wi-Fi capability for both bedside & remote patient monitoring
• Seamless integration with hospital’s EHR & telecom network

Significant Milestones
Proof of concept completed
Design validation in progress
Clinical validation in contract
FDA 510(k) Submission
Soft launch Q4 2018
Product launch Q2 2019

Fundraising
Seeking $750K Seed

Presenting in the
Pulmonology & Critical Care Showcase
Wednesday
September 27
8:10 am - 9:00 am
Cost effective, office-based MRI with cellular spatial resolution

- Compact, single sided MRI with high spatial resolution comparable to histology
- Focused on pelvic region & prostate disease management
- Product pipeline encompasses office MRI, biopsy & ablation tools, & CAD software
- Non-invasive with no unpleasant side effects to patients
- Enables a point-of-care shift, real-time targeted biopsy & focal treatment
- Established reimbursements & attractive return on purchase for practices & hospitals
- Demonstrated safety in a double-blinded prospective trial on 26 adult subjects
- Seasoned management supported by premier clinicians - Vipul Patel, Ash Tewari, Neal Shore, & business experts - Dushyant Chipalkatty, Diego Olego, Martin Bradshaw

Significant Milestones
Exclusive worldwide license to 8 issued & 25 pending patents
Raised $11.6M ($9M NIH & NSF/$1.6M bridge round/$1M Series A) to date

Fundraising
$4.5M Series A

Presenting in the
Advanced Imaging Diagnostics Showcase
Wednesday September 27
10:45 am - 11:35 am
EHR integration, simplified. Redox is the modern integration engine for healthcare

- Through a single connection, users can authorize the exchange of healthcare data with any partner
- Redox maintains connectivity & data standardization across the largest network of health systems, EHRs, & enterprise healthcare applications
- Users see integration projects accelerate to days instead of months/years
- Software developers experience a modern developer environment & standard healthcare-specific APIs
- Redox’s customers include by health systems, software vendors, EHRs, & payors who use the engine to scale interoperability

Significant Milestones
Connected to 120 health systems, 30 EHRs, & 500+ digital health applications
45 employees, HITRUST Certified
Raised $14M in total funding

Funding
Closed $9M Series B in Q1 2017
Non-invasive nasal ventilation platform for treating sedation-related respiratory compromise

- SuperNO₂VA™ nasal platform may be used pre-op, intra-op & post-op for general anesthesia & deep sedation (GADS) cases
- Continuous nasal ventilation system is the only nasal mask on the market that relieves upper airway obstruction
- Ability to measure EtCO₂ aligns with CMS standards of post-operative care guidelines
- Clinical trial demonstrated improved oxygenation & ventilation compared to the current standard of care
- Single-use device, applicable to 60 million procedures in the US
- >8,000 patients have undergone Nasal Oxygenation & Ventilation of the Airway (NOVA) therapy

Significant Milestones
SuperNO₂VA™ mask commercial launch (2016)
Patents issued (utility & design)

Fundraising
Seeking $10M Series B

Presenting in the Pulmonology & Critical Care Showcase Wednesday September 27 8:10 am - 9:00 am
Intelligent solutions for reducing risk & increasing compliance for opioid prescribers & their patients

- OpiSafe provides medical professionals access to all relevant opiate-prescribing patient data (ePROs, PDMP, EHR, & lab results) in one place
- Streamlines tracking opioid use & assists w/ following CDC guidelines
- Improves workflow efficiency & improves outcomes by automating the delivery of clinical assessments
- OpiSafe promotes patient engagement & helps care providers lower liability risks, thus save on medical malpractice
- 450+ practices across the US use OpiSafe resulting in 5K+ lab reports generated & 20K+ PDMP checks per month

Significant Milestones
Signed contracts w/ 12 pain & MAT clinics
Received CO OEDIT Advanced Industries Grant ($250K)

Fundraising
Seeking $750K Seed

RxAssurance
Denver, CO

Rob Valuck, PhD
Co-Founder & CSO

Chris Ennis
Co-Founder & CTO
chris@rxassurance.com

Rick May, MD
CMO

Presenting in the
Health Care IT &
Digital Health Showcase
Tuesday
September 26
9:55 am - 10:35 am

OpiSafe
Reducing the Time Burden of Managing Patients

Automated PDMP Checks
Urine Drug Test
Interactive Assessment Management

OpiSafe reduces clinical time from 5+ minutes to 60 seconds or less

rxassurance.com
Smart access needle preventing lung collapse & hospital admissions post lung biopsy

- Simple, effective & patent protected technology to prevent pneumothorax, a collapsed lung: the leading hospital cost & complication post lung biopsy
- 1 in 3 patients undergoing a lung biopsy suffer from a pneumothorax & many patients require hospitalization for invasive treatment at average cost of $11K per patient
- Sterile, single-use ‘smart’ access needle allows clinicians to seal the biopsy route pre-biopsy; Biopsy carried out through this air tight seal, prevents pneumothorax during or after the procedure
- Patient safely returns home on same day as biopsy with no risk of pneumothorax & no costly hospital admission
- Large growth market: 1.1M lung biopsy procedures globally pa.
- Therapeutic opportunity for prevention of pneumothorax during percutaneous lung ablation

Significant Milestones
Developed prototype
Strong proof of concept data from in vivo studies in porcine model
International clinical validation
Experienced founding team with world class advisors

Fundraising
Seeking €3.5M Seed

Presenting in the Pulmonology & Critical Care Showcase
Wednesday September 27
8:10 am - 9:00 am

In Vivo results in porcine model
1. CT scan before procedure.
2. CT scan after successful delivery of sealant & contrast into pleural cavity with Selio device.
Platform to improve diagnosis & treatment of brain disorders including autism & ADHD

- Data collection & analytic platform to improve diagnosis of & treatment outcomes in neurodevelopmental & brain disorders
- Provides real-time access to the patient’s overall health profile & daily progress across set goals, reducing intervention cycles
- Connects parents, physicians, & therapists through comprehensive reporting, optimizing engagement for daily behavioral health management
- Customizable clinical dashboard, utilizing artificial intelligence for both patient-directed & disease aggregate decision-making

**Significant Milestones**

- Patent filed
- Alpha & beta apps released; beta enrollment in progress
- Established partnership with the Mind Institute at UC Davis
- Raised $1.6M to date in funding

**Fundraising**

- Seeking $4-5M Series A

---

Presenting in the Consumer Health Showcase
**Wednesday**
September 27
9:05 am - 9:45 am
Spinal decompression device for relieving back pain

- VerteCore Lift decompresses the spine utilizing an easy-to-use dual support harness & ratcheting system
- Lightweight device is comfortable & slim enough to be worn under normal clothing allowing patients to continue with normal daily routines while receiving spinal decompression therapy
- Mobile product to address evidence-based treatment for spinal decompression, potentially eliminating the need for long-term opioid use
- Reduces lost worker productivity & minimizes risk of repeated injury due to insufficient recovery

Significant Milestones
- Received FDA approval in Q2 2016
- Indiegogo Campaign resulted in $408K in pre-sales

Fundraising
- Seeking $1 M Seed

Presenting in the Orthopedic Showcase
- Tuesday, September 26
- 10:45 am - 11:35 am

Paul Leake
Co-Founder & CEO
paul.leake@vertecore.com

Paul Montalvo
Co-Founder & Chief Design Officer

Crosby, MS

www.vertecorelift.com
Implantable device to improve vascular access for dialysis patients

Ark is designed to eliminate problems associated with venous access
• Facilitates fistula usage, the preferred method of access incentivized by Medicare
• Acts as a supportive exoskeleton, strengthening the vessel, improving the capability of enduring repeated needle punctures
• Enables earlier vascular access by promoting fistula maturity & restores failed fistulas
• Provides value to hospitals & surgical centers by decreasing inpatient hospitalizations, decreasing the number of hospital days & improving patient outcomes

Significant Milestones
Provisional patent filed
Raised $225K to date from founders

Fundraising
Seeking $750K Seed

Presenting in the Vascular & Neurovascular Showcase: Tuesday, September 26, 2:55 pm - 3:45 pm
Smaller, safer blood pump to help infants & children with heart failure

Oklahoma, OK

Angel Assist is a miniature VAD platform designed specifically for the pediatric population (down to 3kg)

Greatest need is for the smallest children

Current treatment options include 30+ year technology obsolete in adults, off label use of adult devices in larger kids, or doing nothing

The ‘AA’ battery-sized implantable pump was designed to:

- Reduce complications
- Enable hospital discharge
- Substantially reduce the total cost of care

Overall, VADovations seeks to capture underserved niche markets to confirm technology performance, generate revenues, cultivate clinical champions, & then pursue the larger adult heart failure market

Significant Milestones

U.S. Humanitarian Use Designation pending
Raised $30M to date ($5M Series A/$15M convertible debt, $10M grants)

Fundraising
Seeking $10M to commence 1st in Human implants

Presenting in the Cardiovascular Showcase
Wednesday September 27
11:40 am - 12:30 pm

angelassist@vadovations.com
Live cellular imaging using a handheld device for real-time cancer detection

EagleCyte uses dynamic nonlinear microscopy for non-invasive skin pathology

Other companies simplify skin cancer screening; we allow physicians to diagnose immediately

Delivers H&E-quality contrast without dyes

Multiple medical applications for women’s health, neuromuscular, GI oncology, & dermatology

Significant Milestones
Clinical prototype developed
Completed feasibility study

Fundraising
Seeking $8M Series A

Presenting in the Dermatology & Wound Healing Showcase Tuesday September 26 11:40 am - 12:20 pm
Be sure to visit the Innovation Pavilion during these times for demonstrations from the companies listed below:

<table>
<thead>
<tr>
<th>DAY</th>
<th>START</th>
<th>END</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>10:15 am</td>
<td>11:15 am</td>
</tr>
<tr>
<td></td>
<td>3:30 pm</td>
<td>4:00 pm</td>
</tr>
<tr>
<td>Wednesday</td>
<td>8:00 am</td>
<td>9:00 am</td>
</tr>
<tr>
<td></td>
<td>10:15 am</td>
<td>11:15 am</td>
</tr>
</tbody>
</table>
Join us on Tuesday afternoon from 4:00 pm – 5:30 pm in the Convention Center – Grand Ballroom for the MedTech Innovator $500K Competition Finals